MedTrace Logo

Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy

NCT02368587 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-12-05

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of intracoronary or intravenous infusion human umbilical Wharton's jelly-derived Mesenchymal Stem Cell (WJMSC) in patients with ischemic cardiomyopathy secondary to myocardial infarction.

Conditions

  • Ischemic Cardiomyopathy

Interventions

BIOLOGICAL

WJMSCs Vs. placebo

WJMSCs Vs. placebo

BIOLOGICAL

Placebo

WJMSCs Vs. placebo

Sponsors & Collaborators

  • First People's Hospital of Foshan

    collaborator OTHER

  • General Hospital of Armed Police, Beijing

    collaborator UNKNOWN

  • PLA General Hospital, Beijing

    collaborator UNKNOWN

  • Navy General Hospital, Beijing

    lead OTHER

Principal Investigators

  • Ning K Zhang, MS · Navy General Hospital, Beijing

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
17 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-01-01
Completion
2021-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02368587 on ClinicalTrials.gov